ArticlePloS one2025
Optimizing blood alcohol concentration measurement with breath alcohol meter and its preliminary application in evaluating CYP2E1 activity.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An experimental study on the role of naloxone in facilitating alcohol metabolism in acute alcohol intoxication rats.Future science OA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEthanol metabolism in vivo is primarily mediated by CYP2E1 and alcohol dehydrogenase, with CYP2E1 playing the predominant role at high ethanol concentrations. However, it is a difficult problem to evaluate CYP2E1 activity with ethanol as a probe, especially in rats. Currently, high-performance liquid chromatography (HPLC)-based detection of chlorzoxazone is the standard method for evaluating CYP2E1 activity. Nevertheless, this method is labor-intensive, time-consuming, costly, and unsuitable for real-time on-site or multipoint noninvasive monitoring.
objectivesThis study aimed to develop and optimize a noninvasive and rapid method for blood alcohol concentration BAC detection in rats. The optimized approach was subsequently applied to preliminarily assess hepatic CYP2E1 activity.
methodsMale Sprague-Dawley rats were randomly divided into two groups: the immune-mediated liver injury (hepatitis) group and the control group. Hepatitis rats was induced by tail vein injection of Bacillus Calmette-Guerin and lipopolysaccharide, whereas the control rats received an equivalent volume of normal saline. On day 14 of the experiment, following intragastric administration of 56% (v/v) alcohol (5 mL·kg ⁻ ¹), BAC in both groups was measured using a breath alcohol meter. The BAC-time curve was segmented at 46 mg·dL ⁻ ¹: the upper portion was used to assess CYP2E1 activity, while the lower portion reflected alcohol dehydrogenase activity. Liver tissues were collected from rats and observed for histopathological changes using hematoxylin and eosin staining. To validate the accuracy of breath alcoholmeter, headspace gas chromatography was employed. Additionally, HPLC was used to determine plasma chlorzoxazone metabolism, serving as an independent measure of CYP2E1 activity. Based on these findings, we further investigated the potential of ethanol as a probe substrate for assessing the activity of CYP2E1.
resultsThe pathological findings demonstrated that BCG successfully induced immune liver injury in rats. Comparative analysis using both breath alcohol meter and gas chromatography revealed significantly reduced alcohol metabolism in the immune-mediated liver injury rats relative to the control. The gas chromatographic measurements of BAC confirmed the accuracy and reproducibility of the breath alcohol detection method. Furthermore, HPLC analysis demonstrated a marked reduction in CYP2E1 activity in the liver injury rats compared to control.
conclusionThe breath alcohol detection method offers a simple, non-invasive approach that can serve as a viable alternative for assessing hepatic CYP2E1 metabolic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.